following a full submission:
insulin degludec/liraglutide (Xultophy®) is accepted for restricted use within NHS Scotland.
Indication under review: Treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or with basal insulin do not provide adequate glycaemic control.
SMC restriction: for use in patients who are uncontrolled on basal insulin analogues (glycosylated haemoglobin [HbA1c] >7.5% [59mmol/mol]) and for whom a GLP-1 receptor agonist is appropriate as an add-on intensification therapy to basal insulin to obtain glucose control.
In two phase III studies treatment with insulin degludec/liraglutide resulted in a significant reduction from baseline to week 26 in HbA1c compared with the basal insulin comparators.
Download detailed advice206KB (PDF)
Medicine details
- Medicine name:
- insulin degludec/liraglutide (Xultophy)
- SMC ID:
- 1088/15
- Indication:
- Treatment of adults with type 2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or with basal insulin do not provide adequate glycaemic control.
- Pharmaceutical company
- Novo Nordisk Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Restricted
- Date advice published
- 12 October 2015